Xspray Pharma: Q2 – An Eventful Quarter

Redeye leaves its view on Xspray's Q2 report and expects the second half of 2021 to be eventful for the company. Notable events include a BE study readout for the "C-formulation" and submission to FDA under the 505(b)(2) procedure for its improved HyNap-Dasa. Our base case remains SEK 185.

Länk till analysen i sin helhet: https://www.redeye.se/research/818154/xspray-pharma-q2-an-eventful-quarter?utm_source=finwire&utm_medium=RSS